EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT)
7.6500
-0.4000 (-4.97%)
Eyepoint Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative treatments for diseases affecting the eye, particularly those related to retinal and intraocular conditions
The company is dedicated to advancing sustained-release drug delivery systems, enabling patients to receive extended therapeutic benefits from their medications with reduced frequency of administration. Eyepoint's portfolio includes specialized formulations that aim to improve patient outcomes and ease the burden of disease management in ocular health. Through its commitment to research and development, Eyepoint seeks to address unmet medical needs in the field of ophthalmology.
WATERTOWN, Mass., Feb. 03, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQEYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced results from new subgroup analyses from the Phase 2 DAVIO 2 clinical trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E. These data are being presented in two sessions at the Angiogenesis, Exudation, and Degeneration 2024 Meeting held virtually today, February 3, 2024. The presenting speakers are Charles C. Wykoff, M.D., Ph.D., Director of Research, Retina Consultants of Texas, and Carl Regillo, M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University.
NEW YORK, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) on behalf of EyePoint stockholders. Our investigation concerns whether EyePoint has violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, Dec. 23, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) on behalf of EyePoint stockholders. Our investigation concerns whether EyePoint has violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) on behalf of EyePoint stockholders. Our investigation concerns whether EyePoint has violated the federal securities laws and/or engaged in other unlawful business practices.
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (NASDAQEYPT), F45 Training Holdings, Inc. NYSE: FXLVNYSEFXLV)(NYSE: PRGNYSEPRG, and Establishment Labs Holdings Inc. (NASDAQ: ESTANASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (NASDAQEYPT), F45 Training Holdings, Inc. NYSE: FXLVNYSEFXLV)(NYSE: PRGNYSEPRG, and Intuit, Inc. (NASDAQ: INTUNASDAQ). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
San Diego, CA -- (SBWIRE) -- 11/02/2022 -- EyePoint Pharmaceuticals, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
NEW YORK, Oct. 16, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (NASDAQEYPT), Spectrum Pharmaceuticals, Inc. NASDAQ: SPPINASDAQSPPI)(NYSE: FXLVNYSEFXLV, and PROG Holdings, Inc. (NYSE: PRGNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
NEW YORK, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Compass Minerals International, Inc. (NYSECMP), EyePoint Pharmaceuticals, Inc. NASDAQ: EYPTNASDAQEYPT)(NYSE: FXLVNYSEFXLV, and PROG Holdings, Inc. (NYSE: PRGNYSE). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) on behalf of EyePoint stockholders. Our investigation concerns whether EyePoint has violated the federal securities laws and/or engaged in other unlawful business practices.
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) investors concerning the Company’s possible violations of the federal securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of EyePoint Pharmaceuticals, Inc. (“EyePoint” or “the Company”) (NASDAQEYPT) for violations of the securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of EyePoint Pharmaceuticals, Inc. (“EyePoint” or the “Company”) (NASDAQEYPT) on behalf of investors concerning the Company’s possible violations of federal securities laws.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of EyePoint Pharmaceuticals, Inc. (“EyePoint” or “the Company”) (NASDAQEYPT) for violations of the securities laws.
